FOR IMMEDIATE RELEASE
Boca Raton, FL — Aventusoft, the company behind HEMOTAG®, a breakthrough Heart Failure management system, is proud to announce its acceptance into the MedTech Innovator 2025 Asia Pacific Accelerator Cohort, a premier program supporting high-potential health technologies seeking to scale across Asia-Pacific markets. We are one of only 20 companies representing the top 3% of nearly 550+ global applicants chosen for this year’s program.
MedTech Innovator is the world’s largest accelerator for medical technology startups. The highly competitive program provides participants with world-class mentorship, strategic guidance, and access to a robust network of investors, providers, payers, manufacturers, and industry experts. Bringing together world-class healthcare institutions, investors, and industry leaders to help cutting-edge medical technologies navigate the complex pathways of clinical adoption, regulatory approvals, and strategic partnerships across the region, ultimately improving patient outcomes across APAC and globally.
“Being selected for this year’s cohort is both an honor and a powerful affirmation of our mission to provide A New Weapon in the Fight Against Heart Failure.” said Kaustubh Kale, Founder and CEO of HEMOTAG. ” Our technology platform marks a critical advancement in overcoming persistent challenges in heart failure management. Being part of this program provides a strategic opportunity to validate our solution, deepen industry partnerships, and accelerate our commercialization trajectory to bring HEMOTAG’s life-saving technology to patients and clinicians throughout the Asia-Pacific region.”
HEMOTAG was selected for its groundbreaking, non-invasive technology that delivers real-time intracardiac performance markers across multiple heart chambers—empowering clinicians to manage heart failure with greater precision. By enabling earlier intervention, reducing hospital readmissions, and improving outcomes, HEMOTAG’s Full-Spectrum Heart Failure Management System addresses longstanding clinical gaps where traditional systems fall short. Its development strongly aligns with MedTech Innovator’s mission to advance patient care through transformative innovation.
The 2025 cohort companies will present at major industry events including Innovator Summit on June 25-26 in Mountain View, California and the Grand Finals in Singapore at the end of October, where they will also compete for up to USD 300,000 in non-dilutive cash prizes and awards.
About HEMOTAG
Founded in 2024 and headquartered in Boca Raton, FL, HEMOTAG® is advancing the global standard of care with its Full-Spectrum Heart Failure Management System. The company is focused on developing and commercializing the world’s first intracardiac chamber performance-based technologies—offering a new paradigm in early- to late-stage heart failure management, heart disease detection, and hemodynamics-based diagnostics. HEMOTAG’s platform combines cutting-edge quad-sensor device, mobile application, and cloud-based diagnostics to deliver clinical-grade insights across care settings—from hospitals and ambulatory centers to emergency departments and the home. These solutions are designed to fill critical gaps in cardiovascular care and enable earlier, more precise interventions.
Developed by Aventusoft, HEMOTAG is backed by non-dilutive funding from the National Institutes of Health (NIH), Department of Defense (DoD), National Science Foundation (NSF), and other federal agencies. Participation in the accelerator positions HEMOTAG for international growth and strengthens its mission to improve cardiac care for aging populations and communities globally.
Together, lets make heart failure manageable—not a life sentence. Learn more at: hemotag.com
About MedTech Innovator
MedTech Innovator is the world’s largest accelerator of medical technology companies. Its mission is to improve human health by accelerating the growth of companies that are transforming care. MedTech Innovator has been a catalyst for groundbreaking healthcare solutions, reviewing well over 14,000 applicants and fostering the growth of 717 companies globally that have collectively raised over USD 9.5 billion in follow-on funding, transforming the lives of millions. For more information about MedTech Innovator Asia Pacific, its annual programs, portfolio of industry-leading startups, and insights on trends, visit MedTech Innovator Asia Pacific’s website, follow the U.S. organization on LinkedIn U.S. and its APAC program at LinkedIn APAC, and subscribe to its monthly newsletter.
Media Contact
David Flores
Director of Marketing
david@hemotag.com
+1 561-234-4040